Current Report Filing (8-k)

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K
___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): January 27, 2017

 

OWC PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)

 

Commission File No.: 0-54856

 

Delaware	98-0573566
(State of Incorporation)	(I.R.S. Employer Identification No.)
30 Shacham Street, P.O.B. 8324, Petach Tikva, Israel	4918103
(Address of Principal Executive Offices)	(ZIP Code)

 

Registrant's Telephone Number, including area code: 972 (0) 3-758-2657

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01 Other Events.

On January 27, 2017, OWC Pharmaceutical Research Corp. issued a press release announcing that Ms. Miri Sani has accepted her nomination to the Company's Advisory Board. The press release is attached to this Form 8-K as Exhibit 99.1.

Exhibit No.	Description
99.1	Press Release issued by OWC Pharmaceutical Research Corp. dated January 27, 2017.

 

	OWC Pharmaceutical Research Corp.
	By:	/s/  Mordechai Bignitz
	Name:	Mordechai Bignitz
	Title:	Chief Executive Officer

Date: January 27, 2017